Newegg Commerce Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Newegg Commerce Inc trades at $11.69 (market cap $243.30M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.45 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 9.3× Newegg Commerce Inc's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| NEGG | SLS | |
|---|---|---|
Market Cap | $243.30M | $2.27B |
Volume | 41,252 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $92.74 | $15.46 |
52-Week Low | $11.49 | $1.39 |
Typical Hold Time | 14 Days | — |
Enterprise Value | $213.53M | $2.14B |
Signals from Pluang's Aura AI — not financial advice
NEGG stock trades at $12.01, up 0.84% today, but technical indicators are bearish with moving averages signaling a downtrend. The company shows improving fundamentals, with revenue of $1.44B in 2025 and a net income margin turning positive to 0.68% in 2026 projections. Recent news highlights partnerships with Western Digital and Hewlett Packard Enterprise to support IT infrastructure, though insider selling has created negative sentiment.
The outlook is mixed; earnings beats and margin improvement offer upside, but the stock faces bearish technicals and a consensus price target of $7.75 below the current price. Key risks include volatile cash flows and high liabilities, while a single analyst rates it Buy. Investors should weigh operational progress against valuation concerns and market sentiment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →